Evidence map›Paper›PMID 42349695›Full record

ArticleAnnals of epidemiology2026

GLP-1 receptor agonist medications for weight loss: Sociodemographic patterns of awareness, use, and access in a U.S. national cohort.

Jenna Sanborn, Sasha A Fleary, Denis Nash, Kate Penrose, Angela M Parcesepe, Rachael Piltch-Loeb, Josefina Nuñez, Yanhan Shen, McKaylee M Robertson

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jenna SanbornInstitute for Implementation Science in Population Health, City University of New York, Graduate School of Public Health and Health Policy, New York, NY, United States; Department of Epidemiology & Biostatistics, Graduate School of Public Health and Health Policy, The City University of New York, New York, NY, USA. Electronic address: jenna.sanborn@sph.cuny.edu.
Sasha A FlearyInstitute for Implementation Science in Population Health, City University of New York, Graduate School of Public Health and Health Policy, New York, NY, United States; Department of Community Health and Social Sciences, Graduate School of Public Health and Health Policy, The City University of New York, New York, USA.
Denis NashInstitute for Implementation Science in Population Health, City University of New York, Graduate School of Public Health and Health Policy, New York, NY, United States; Department of Epidemiology & Biostatistics, Graduate School of Public Health and Health Policy, The City University of New York, New York, NY, USA.
Kate PenroseInstitute for Implementation Science in Population Health, City University of New York, Graduate School of Public Health and Health Policy, New York, NY, United States.
Angela M ParcesepeUniversity of North Carolina at Chapel Hill Gillings School of Public Health and Carolina Population Center, Chapel Hill, NC, USA.
Rachael Piltch-LoebInstitute for Implementation Science in Population Health, City University of New York, Graduate School of Public Health and Health Policy, New York, NY, United States; Department of Environmental Occupational Geospatial Health, Graduate School of Public Health and Health Policy, The City University of New York, New York, USA.
Josefina NuñezInstitute for Implementation Science in Population Health, City University of New York, Graduate School of Public Health and Health Policy, New York, NY, United States.
Yanhan ShenInstitute for Implementation Science in Population Health, City University of New York, Graduate School of Public Health and Health Policy, New York, NY, United States.
McKaylee M RobertsonInstitute for Implementation Science in Population Health, City University of New York, Graduate School of Public Health and Health Policy, New York, NY, United States; Department of Epidemiology & Biostatistics, Graduate School of Public Health and Health Policy, The City University of New York, New York, NY, USA.

Funding

Research Services CoreP2CHD050924 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KAREN B GUZZO · 2015 to 2026
$9.6M
Following a U.S. National Cohort of Vulnerable Men to Improve HIV Prevention and CareUH3AI133675 · NIAID · GRADUATE SCHOOL OF PUBLIC HEALTH AND HEALTH POLICY · PI GROV, CHRISTIAN · 2019 to 2021
$6.9M
Brief digital intervention to increase COVID-19 vaccination among individuals with anxiety or depressionRF1MH132360 · NIMH · GRADUATE SCHOOL OF PUBLIC HEALTH AND HEALTH POLICY · PI NASH, DENIS, PARCESEPE, ANGELA · 2022 to 2022
$3.3M
NIAID NIH HHS UH3 AI133675NICHD NIH HHS P2C HD050924NIMH NIH HHS RF1 MH132360
6 · The paper itself

Abstract

purposeTo describe patterns of glucagon-like peptide-1 receptor agonist (GLP1-RA) medication awareness, use, and access in a US adult cohort.

methodsUsing self-reported December 2023 data from a nationwide cohort (N = 4555), we examined predictors of awareness, use (≤3 years), and inability to access GLP1-RA medications. Poisson regression with robust standard errors estimated age/sex-adjusted prevalence ratios. Analyses were conducted overall and among participants meeting FDA clinical-eligibility criteria (BMI ≥30 kg/m² or ≥27 kg/m² + ≥1 comorbidity; N = 1883).

resultsAwareness was 81.6%; use was 8.3% overall, 13.4% among clinically-eligible participants, and 4.0% among ineligible participants. Overall, use was highest at ages 30-39 and 50-64 and among Hispanic and Black adults, parents, smokers, and those with healthcare barriers. Among clinically-eligible participants, use was lower among men (aPR=0.76, 95% CI: 0.60-0.96) and those with healthcare access barriers (aPR=0.47 [0.35-0.63]), and higher among those with income ≥ $100,000 versus < $49,000 (aPR=1.49 [1.12-1.98]). Among those who attempted treatment, 49.9% were unsuccessful; inability was more common for those with healthcare barriers (aPR=1.42 [1.14-1.77]).

conclusionsGLP1-RA awareness is high, but predictors of uptake and access differ by eligibility. Sociodemographic factors predicted uptake in the full cohort; income, sex, and healthcare barriers were significant predictors among clinically-eligible adults.

Indexed as

Glucagon-Like Peptide-1 Receptor AgonistsHealth Knowledge, Attitudes, PracticeHealth Services AccessibilityObesityWeight LossAdultAgedCohort StudiesFemaleGlucagon-Like Peptide-1 ReceptorHumansMaleMiddle AgedSociodemographic FactorsSocioeconomic FactorsUnited StatesGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsAnd health knowledgeAttitudesCohort studiesGlucagon-like peptide 1 receptor agonistsPracticeRisk factorsSocioeconomic factorsUnited States

Identifiers

PMID42349695
PMCPMC13401313

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.